SRR10899985
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.400
- INTERFERON_ALPHA_RESPONSE+0.400
- INTERFERON_GAMMA_RESPONSE+0.400
- MTORC1_SIGNALING+0.400
- OXIDATIVE_PHOSPHORYLATION+0.400
- PROTEIN_SECRETION+0.400
- TNFA_SIGNALING_VIA_NFKB+0.400
- ADIPOGENESIS+0.300
- APOPTOSIS+0.300
- COMPLEMENT+0.300
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.400
- ANGIOGENESIS-0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.200
- MYOGENESIS-0.200
- APICAL_SURFACE-0.100
- ESTROGEN_RESPONSE_EARLY-0.100
- ESTROGEN_RESPONSE_LATE-0.100
- KRAS_SIGNALING_DN-0.100
- APICAL_JUNCTION+0.000
- HEDGEHOG_SIGNALING+0.000
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | c340b651-bd01-4194-a67b-e801d0feeb2b | — | — | 0.861 |
| 2 | SRR12696807 | — | — | 0.856 |
| 3 | SRR5903550 | — | cohortA4 | 0.843 |
| 4 | C3N-02087 | — | cohortA1 | 0.837 |
| 5 | BS_XF0ZX2B3 | Supratentorial Ependymoma | — | 0.836 |
| 6 | E97A62A3-E4D3-435C-9165-C0075358578E | — | — | 0.835 |
| 7 | ERR2208906 | — | — | 0.830 |
| 8 | BS_XF0ZX2B3 | EPN | Supratentorial EPN | 0.828 |
| 9 | SRR6013490 | — | cohortA4 | 0.825 |
| 10 | SRR6013516 | — | cohortA1 | 0.824 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.400 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.400 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.400 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.400 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.400 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.400 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.400 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.300 | Inavolisib | — uncovered |
| APOPTOSIS | 0.300 | Idelalisib | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.300 | Temsirolimus | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.300 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.300 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.200 | Idelalisib | — uncovered |